Pharmacokinetic Properties of Dapagliflozin in Patients with Stage 4 Chronic Kidney Disease
In conclusion, no clinically significant accumulation of dapagliflozin was observed in patients with stage 4 CKD.
Authors
- Ancheng Gu
- Yerong Wei (ORCID: https://orcid.org/0000-0002-5552-0316)
- Yaya Yang (ORCID: https://orcid.org/0009-0005-3247-1688)
- Bianxiang Hu (ORCID: https://orcid.org/0000-0001-5112-6584)
- Min Liang (ORCID: https://orcid.org/0000-0002-0613-2077)
- Zhongyuan Xu (ORCID: https://orcid.org/0000-0002-7397-4637)
- Di Xie (ORCID: https://orcid.org/0000-0003-3600-2983)
- Jun Li (ORCID: https://orcid.org/0000-0003-4353-5761)
- Lei Zhang (ORCID: https://orcid.org/0000-0003-4462-8572)
- Dan Li (ORCID: https://orcid.org/0000-0001-7138-4898)
- Zhijian Guo (ORCID: https://orcid.org/0009-0001-4722-6117)
- Xiaobing Yang (ORCID: https://orcid.org/0000-0003-4950-4245)
- Yan Huang (ORCID: https://orcid.org/0009-0003-1498-7440)
- Jiali He
- Xianglan Huang
- Wanwen Cao
- Jun Wang (ORCID: https://orcid.org/0009-0009-7255-8840)
Institutions
- National Medical Products Administration (CN)
- Nanfang Hospital (CN)
- National Clinical Research (US)
- Southern Medical University (CN)
Publication Details
- Journal
- American Journal of Nephrology
- Published
- 2025-03-14
- DOI
- https://doi.org/10.1159/000544936
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Chinese Pharmaceutical Association
- Southern Medical University
- Nanfang Hospital
- National Science and Technology Major Project
- National Key Research and Development Program of China
- Basic and Applied Basic Research Foundation of Guangdong Province